Compare IDEXX Laboratories, Inc. (IDXX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Spotify Technology — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Spotify Technology trades at $529.14 (market cap $108.22B). The key difference: Spotify Technology is far larger — about 2.7× IDEXX Laboratories, Inc.'s market cap, and Spotify Technology is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Spotify Technology for 111 Days on average.
| IDXX | SPOT | |
|---|---|---|
Market Cap | $40.43B | $108.22B |
Volume | 692,164 | 1,655,796 |
Sector | Health | Media |
52-Week High | $766.68 | $692.04 |
52-Week Low | $504.70 | $412.75 |
Typical Hold Time | 46 Days | 111 Days |
Enterprise Value | $41.32B | $98.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Spotify (SPOT) trades at $526.42, up 2.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamental improvement with revenue growth from $15.7B to $17.2B in 2025 and net income surging to $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst sentiment remains overwhelmingly positive with 62% buy ratings and a $606.50 consensus target.
The outlook remains favorable with expanding gross margins and positive cash flow trends, though competition and market volatility present risks. With strong institutional support and upcoming Q3 earnings on October 22, 2026, SPOT offers growth potential but requires monitoring of execution against elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
